This review provides practical guidance on the use of cangrelor, an intravenous P2Y12 inhibitor, in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
May inform cangrelor use in ACS-PCI; leaves open optimal integration with oral P2Y12 inhibitors.
Cangrelor, the first and currently only available intravenous P2Y 12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention. The rationale for cangrelor use is most robust in patients requiring an immediate, profound, and predictable level of P2Y 12 inhibition – especially in patients with acute coronary syndromes. Herein we summarize the drug development program and reflect on practical considerations for clinicians on cangrelor use in the acute setting surrounding percutaneous coronary intervention, including selection of patients, concomitant administration of glycoprotein IIb/IIIa inhibitors and transition strategies from intravenous to oral P2Y 12 receptor antagonists.
No takes yet. Share an insight, caveat, or question.
Leonardi et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: